Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brasil.
J Bras Pneumol. 2012 Jan-Feb;38(1):50-6. doi: 10.1590/s1806-37132012000100008.
To determine the effects that mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene and deletion of the glutathione S-transferase (GST) genes mu-1 (GSTM1) and theta-1 (GSTT1) have on the clinical course of cystic fibrosis (CF) in patients residing in the southeastern region of Brazil.
The study sample consisted of all consecutive CF patients treated at the Hospital de Clínicas School of Medical Sciences of the State University at Campinas between March of 2002 and March of 2005. We included 66 CF patients. Genomic DNA was analyzed by polymerase chain reaction and restriction endonuclease digestion for the identification of the genotypes.
The DF508 mutation of the CFTR gene was found in 44 patients (66.7%). The null genotypes GSTM1, GSTT1 and GSTM1/GSTT1 were found in 40.9%, 15.2%, and 3.0% of the patients, respectively. The DF508 CFTR mutation was more common in patients diagnosed with CF before 2.5 years of age than in those diagnosed later (75.5% vs. 41.2%; p = 0.008). The frequency of the DF508 CFTR mutation, as well as of the GSTM1 and GSTT1 genotypes, was not found to be associated with gender, ethnicity, pulmonary disease status, or pancreatic disease status.
When the patients were stratified by clinical and epidemiological features, the frequencies of the GSTM1 and GSTT1 null genotypes were similar, suggesting that the inherited absence of these enzymatic pathways does not alter the course of CF. However, the high frequency of the DF508 CFTR mutation found in younger children suggests that it influences the age at diagnosis of CF in this region of Brazil.
确定囊性纤维化跨膜电导调节因子(CFTR)基因突变和谷胱甘肽 S-转移酶(GST)基因 mu-1(GSTM1)和 theta-1(GSTT1)缺失对居住在巴西南部的囊性纤维化(CF)患者临床病程的影响。
本研究样本包括 2002 年 3 月至 2005 年 3 月期间在坎皮纳斯州立大学临床医学院治疗的所有连续 CF 患者。共纳入 66 例 CF 患者。通过聚合酶链反应和限制性内切酶消化分析基因组 DNA 以鉴定基因型。
在 44 名患者(66.7%)中发现 CFTR 基因的 DF508 突变。GSTM1、GSTT1 和 GSTM1/GSTT1 的无效基因型分别在 40.9%、15.2%和 3.0%的患者中发现。在 2.5 岁之前被诊断为 CF 的患者中,DF508 CFTR 突变更为常见(75.5%比 41.2%;p = 0.008)。DF508 CFTR 突变的频率以及 GSTM1 和 GSTT1 基因型与性别、种族、肺部疾病状态或胰腺疾病状态均无关。
当根据临床和流行病学特征对患者进行分层时,GSTM1 和 GSTT1 无效基因型的频率相似,表明这些酶途径的遗传缺失不会改变 CF 的病程。然而,在年龄较小的儿童中发现的 DF508 CFTR 突变的高频率表明,它影响了巴西该地区 CF 的诊断年龄。